We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 2.99% | 27.60 | 27.60 | 28.00 | 28.00 | 27.00 | 27.40 | 613,915 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.61 | 127.38M |
TIDMEKF
RNS Number : 9905G
EKF Diagnostics Holdings PLC
26 November 2015
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Trading update
EKF Diagnostics Holdings plc (AIM: EKF), announces a trading update for the 12 months to 31 December 2015.
As announced on 11 November 2015, Ron Zwanziger has joined the Board as Non-Executive Chairman and is undertaking a review of the business which is expected to complete before the end of the year.
The initial findings of the review are that the Company expects to achieve full year revenues of approximately GBP32 million. There are likely to be a number of items which will materially affect the Company's profit before tax for the year, including:
-- the partial or complete impairment of the Molecular division. Discussions regarding the divestment or closure of the Molecular division are still ongoing;
-- a provision against, or write off of, specific debtors; and
-- the closure costs of the STI site in Sanford, which the Company announced on 12 November 2015.
The management team is making progress in realigning its cost base to with the goal of achieving positive cash generation in the early part of next year.
In the near term the Board composition will change to having two executives and five non-executives including some external additions. Following the sad passing of Kevin Wilson last week, David Evans has now been appointed Chair of the Audit Committee.
EKF Diagnostics Holdings plc Tel: 029 2071 0570 Ron Zwanziger, Chairman Tel: +1 339 221 6282 David Evans, Deputy Non-Executive Mob: 07740 084 452 Chairman Julian Baines, CEO Mob: 07788 420 859 Paul Foulger, CFO Mob: 07710 989 255 Panmure Gordon (UK) Limited Tel: 020 7886 2500 Robert Naylor (Corporate Finance) Paul Fincham (Corporate Finance) Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFSDLVLEFIE
(END) Dow Jones Newswires
November 26, 2015 02:00 ET (07:00 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions